Discover and read the best of Twitter Threads about #ASCO20BD
Most recents (1)
So many great abstracts to peruse for #ASCO20. Some themes: weekly regimens, anti-BCMA therapies, MRD, & high-risk disease. By abstract #, here are 10(ish) #ASCO20 abstracts that stood out to me for their clinical relevance and intrigue. Long thread incoming! #mmsm #ASCO20BD /1
Plenary LBA3: KRd vs. VRd. No data yet until May 28, but this will be relevant no matter what the outcome is! Note that most high-risk patients were not included in this study. Don't think we'll have a final answer on this debate though! meetinglibrary.asco.org/record/186906/… #mmsm #ASCO20BD /2
#100: Phase I trial of Teclistamab, a bispecific BCMA x CD3 T-cell engager, showed reasonable rates of CRS (56%, all <grade 3). ORR was 38% at doses >38.4 ug/kg. 7/9 (78%) responded at highest dose (2 were CR + MRD-neg at 10^-6). #mmsm #ASCO20BD meetinglibrary.asco.org/record/186864/… /3
